A Phase 2, Single-Arm Study of Abemaciclib for Treatment of Advanced Soft Tissue and Bone Sarcoma Identified as having CDK Pathway Alteration

Protocol No
IIT-CHARLSON-BOAST
Principal Investigator
John Charlson
Phase
II
Summary
In this study we want to find out more about the drug Abemaciclib in people with metastatic or unresectable soft tissue sarcoma or bone sarcoma. We want to find out whether Abemaciclib has anti-tumor effects that could potentially shrink the tumor. The FDA has approved Abemaciclib for treatment in breast cancer, but Abemaciclib is not approved by the FDA for the treatment of sarcoma. We do not yet know if it will help treat this cancer
Description
Abemaciclib for Treatment of Advanced Bone and Soft Tissue Sarcoma Identified as Having CDK Pathway Alteration
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: